Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MS at the Limits 2022 | DMT management – where disease biology and treatment algorithms meet

Emma Tallantyre, MD, PhD, Cardiff University, Cardiff, UK, addresses multiple sclerosis (MS) biology and whether the current disease-modifying therapy (DMT) algorithms are matching up to the biology or not. She gives an overview of the mechanisms underlying MS, including the important role of inflammation in disease progression. Moreover, she highlights neurodegeneration as a fundamental aspect of the disease pathophysiology, and some of the compensation strategies which can sometimes become exhausted as the disease progresses. Importantly, disease biology can evolve throughout the course of MS in any given patient. Current DMTs focus on immune modulation, however, there is a need for new agents that are neuroprotective, neuroregenerative, or remyelinating. This interview took place during the 2022 Multiple Sclerosis at the Limits Conference in London, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


In the last 5 years, Dr Tallantyre has received honorarium for consulting work from Biogen, Janssen, Merck, Novartis, and Roche. She has received travel grants to attend or speak at educational meetings from Biogen, Merck, Roche, Takeda and Novartis.